{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:28:22Z","timestamp":1794490102740,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41375-025-02814-0","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:20:06Z","timestamp":1764746406000},"page":"178-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4801-5048","authenticated-orcid":false,"given":"Enrico","family":"Attardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-7187","authenticated-orcid":false,"given":"Ryunosuke","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-631X","authenticated-orcid":false,"given":"Guilherme","family":"Sapinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-3496","authenticated-orcid":false,"given":"Lukasz","family":"Gondek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0992","authenticated-orcid":false,"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Lok","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9918","authenticated-orcid":false,"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Versino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Julia","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-7284","authenticated-orcid":false,"given":"Sara","family":"Torres-Esquius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Jerez Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"L\u00f3pez-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mart\u00ednez-Laperche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1445-7947","authenticated-orcid":false,"given":"Hussein","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-1509","authenticated-orcid":false,"given":"Valeria","family":"Visconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin G.","family":"Kulasekararaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-4346","authenticated-orcid":false,"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-5374","authenticated-orcid":false,"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2814_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658\u201370.","journal-title":"Cancer Cell"},{"key":"2814_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141:534\u201349.","journal-title":"Blood"},{"key":"2814_CR3","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1038\/s41375-022-01729-4","volume":"36","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Zawit M, Durrani J, Shen W, Bahaj W, Kewan T, et al. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022;36:2827\u201334.","journal-title":"Leukemia"},{"key":"2814_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood.2022017715","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Bowman TV, Godley LA. DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023;141:1544\u201352.","journal-title":"Blood"},{"key":"2814_CR5","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","volume":"7","author":"A Maierhofer","year":"2023","unstructured":"Maierhofer A, Mehta N, Chisholm RA, Hutter S, Baer C, Nadarajah N, et al. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv. 2023;7:7346\u201357.","journal-title":"Blood Adv"},{"key":"2814_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.stem.2021.08.004","volume":"28","author":"TM Chlon","year":"2021","unstructured":"Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Kuenzi Davis A, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021;28:1966\u201381.e6.","journal-title":"Cell Stem Cell"},{"key":"2814_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/ajh.27091","volume":"98","author":"TM Chlon","year":"2023","unstructured":"Chlon TM, Patnaik MM. Germline DDX41 mutant predisposition syndromes: slow driver states to hematological malignancies. Am J Hematol. 2023;98:1673\u20136.","journal-title":"Am J Hematol"},{"key":"2814_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.seminhematol.2024.01.012","volume":"61","author":"A Kishtagari","year":"2024","unstructured":"Kishtagari A, Corty RW, Visconte V. Clonal hematopoiesis and autoimmunity. Semin Hematol. 2024;61:3\u20138.","journal-title":"Semin Hematol"},{"key":"2814_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2021015328","volume":"140","author":"N Duployez","year":"2022","unstructured":"Duployez N, Largeaud L, Duchmann M, Kim R, Rieunier J, Lambert J, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140:756\u201368.","journal-title":"Blood"},{"key":"2814_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41375-024-02180-3","volume":"38","author":"M S\u00e9bert","year":"2024","unstructured":"S\u00e9bert M, Freiman L, Chaffaut C, Guerci A, Peterlin P, Th\u00e9pot S, et al. Clinical impact of genetic alterations including germline DDX41 mutations in MDS\/low-blast count AML patients treated with azacitidine-based regimens. Leukemia. 2024;38:918\u201322.","journal-title":"Leukemia"},{"key":"2814_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, Rahm\u00e9 R, Raffoux E, Sicre de Fontbrune F, et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134:1441\u20134.","journal-title":"Blood"},{"key":"2814_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood.2023020209","volume":"142","author":"S Cheloor Kovilakam","year":"2023","unstructured":"Cheloor Kovilakam S, Gu M, Dunn WG, Marando L, Barcena C, Nik-Zainal S, et al. Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023;142:1185\u201392.","journal-title":"Blood"},{"key":"2814_CR13","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","volume":"10","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Robin M, Godley LA, Drozd-Soko\u0142owska J, W\u0142odarski MW, Raj K, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e994\u20131005.","journal-title":"Lancet Haematol"},{"key":"2814_CR14","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/ajh.27070","volume":"98","author":"A Bataller","year":"2023","unstructured":"Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023;98:1780\u201390.","journal-title":"Am J Hematol"},{"key":"2814_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","volume":"7","author":"C Saygin","year":"2023","unstructured":"Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023;7:549\u201354.","journal-title":"Blood Adv"},{"key":"2814_CR16","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"2814_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2023-186863","volume":"142","author":"E Bernard","year":"2023","unstructured":"Bernard E, Hasserjian R, Greenberg PL, Arango Ossa JE, Creignou M, Nannya Y, et al. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood. 2023;142:997.","journal-title":"Blood"},{"key":"2814_CR18","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122\u201331.","journal-title":"Blood Adv"},{"key":"2814_CR19","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2022018896","volume":"141","author":"T Kewan","year":"2023","unstructured":"Kewan T, Bahaj W, Durmaz A, Aly M, Ogbue OD, Carraway HE, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768\u201372.","journal-title":"Blood"},{"key":"2814_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2814_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2814_CR22","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2814_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2814_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2814_CR25","doi-asserted-by":"crossref","unstructured":"Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, et al. Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria. J Clin Oncol. 2022;41:Jco2200710.","DOI":"10.1200\/JCO.22.00710"},{"key":"2814_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","volume":"6","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022;6:528\u201332.","journal-title":"Blood Adv"},{"key":"2814_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1182\/blood.2021015135","volume":"140","author":"P Li","year":"2022","unstructured":"Li P, Brown S, Williams M, White T, Xie W, Cui W, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022;140:716\u201355.","journal-title":"Blood"},{"key":"2814_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","volume":"37","author":"S Huber","year":"2023","unstructured":"Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, et al. AML classification in the year 2023: how to avoid a Babylonian confusion of languages. Leukemia. 2023;37:1413\u201320.","journal-title":"Leukemia"},{"key":"2814_CR29","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstr\u00f6m-Lindberg E, Bowen D, Ad\u00e8s L, Cermak J, del Ca\u00f1izo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood"},{"key":"2814_CR30","doi-asserted-by":"crossref","unstructured":"Kewan T, Bahaj W, Durmaz A, Aly MM, Ogbue OD, Carraway HE, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768\u201372.","DOI":"10.1182\/blood.2022018896"},{"key":"2814_CR31","doi-asserted-by":"crossref","unstructured":"Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023;37:717\u20139.","DOI":"10.1038\/s41375-023-01820-4"},{"key":"2814_CR32","first-page":"3122","volume":"141","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Prata PH, Catto LFB, Durmaz A, Larcher L, Sebert M, et al. IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2023;141:3122\u20135.","journal-title":"Blood"},{"key":"2814_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02814-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02814-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02814-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:05:08Z","timestamp":1767985508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02814-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2814"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02814-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Review and collection of clinical and molecular data were performed in accordance with the protocols and written consent approved by the institutional review boards of each participating institutions and guidelines set forth by the Declaration of Helsinki. This study was approved by the Cleveland Clinic Institutional Board Review under protocol #5024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent obtained according to the protocols approved by the Institutional Review Board of the participating institutions and in accordance with the ethical principles set forth by the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}